# Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

> **NCT06795503** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 1462 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** Docetaxel plus cyclophosphamide
- **DRUG:** Epirubicin, cyclophosphamide plus paclitaxel

## Key facts

- **NCT ID:** NCT06795503
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2028-08
- **Final completion:** 2031-07
- **Target enrollment:** 1462 (ESTIMATED)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06795503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06795503, "Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06795503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*